Keros Therapeutics
KROS
139 hedge funds and large institutions have $480M invested in Keros Therapeutics in 2025 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 59 increasing their positions, 34 reducing their positions, and 43 closing their positions.
74% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 34
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
12% more capital invested
Capital invested by funds: $429M → $480M (+$51M)
2.12% less ownership
Funds ownership: 90.59% → 88.46% (-2.1%)
11% less funds holding
Funds holding: 156 → 139 (-17)
19% less call options, than puts
Call options by funds: $13.3M | Put options by funds: $16.4M
37% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 43
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$52.7M |
| 2 |
MAP
Madison Avenue Partners
New York
|
+$36.3M |
| 3 |
WSL
Western Standard LLC
Los Angeles,
California
|
+$18.9M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$7.08M |
| 5 |
Janus Henderson Group
London,
|
+$6.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nuveen
Charlotte,
North Carolina
|
-$52.3M |
| 2 |
JP Morgan Chase
New York
|
-$34.5M |
| 3 |
Morgan Stanley
New York
|
-$11.1M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$7.7M |
| 5 |
DS
DRW Securities
Chicago,
Illinois
|
-$4.74M |
KROS Hedge Fund Activity: Q2 2025 in Review
139 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Keros Therapeutics (KROS) for Q2 2025, worth a combined $480M — up 12% from $429M a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of KROS and 27 opened new positions — a net loss of 16 holders — while 34 trimmed existing stakes and 59 added.
The largest buyer was ADAR1 Capital Management, adding an estimated $52.7M. The largest seller was Nuveen, cutting an estimated $52.3M.
- 139 institutional investors held Keros Therapeutics (KROS) as of Q2 2025, down from 156 in Q1 2025.
- Funds reported $480M of Keros Therapeutics stock for Q2 2025, up 12% quarter-over-quarter.
- 27 funds opened new Keros Therapeutics positions in Q2 2025 and 43 closed out, a net change of -16 holders.
- The largest Keros Therapeutics buyer in Q2 2025 was ADAR1 Capital Management, an estimated $52.7M added.
- The largest Keros Therapeutics seller in Q2 2025 was Nuveen, an estimated $52.3M sold.
Based on aggregated 13F filings for Q2 2025.